Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › leukemia

Leukemia

Part of Cancer

Subtypes of Leukemia

Acute Myeloid Leukemia 29 Acute Lymphoblastic Leukemia 16 Acute Promyelocytic Leukemia 5 Chronic Lymphocytic Leukemia 5 Chronic myelomonocytic leukemia 3 Blastic plasmacytoid dendritic cell neoplasm 1 Myeloid sarcoma 1 Small lymphocytic lymphoma 1

64 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for leukemia

814 trials tracked for leukemia: 116 in phase 3 or 4 and 47 with published results. The most-cited published study has 1233 citations.

814Trials tracked
116Phase 3 & 4
0Recruiting
47With published results
Phase distribution
Phase 4 16 Phase 3 100 Phase 2 587 Phase 1 51 Other / NA 60
  1. Phase 3 A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation Completed · 1,233 cited
  2. Phase 3 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy Completed · 750 cited
  3. Phase 3 TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Completed · 535 cited
  4. Phase 3 A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed · 491 cited
  5. Phase 3 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Completed · 358 cited
  6. Phase 3 Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Completed · 332 cited
Show 44 more trials
  1. Phase 3 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed · 251 cited
  2. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 248 cited
  3. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 238 cited
  4. Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 223 cited
  5. Phase 3 Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) Completed · 211 cited
  6. Phase 3 Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Completed · 210 cited
  7. Phase 3 Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Completed · 167 cited
  8. Phase 3 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed · 153 cited
  9. Phase 3 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy Completed · 143 cited
  10. Phase 3 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy Completed · 124 cited
  11. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  12. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 111 cited
  13. Phase 3 Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS Completed · 109 cited
  14. Phase 3 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed · 108 cited
  15. Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed · 101 cited
  16. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 100 cited
  17. Phase 3 Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) Completed · 97 cited
  18. Phase 3 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Completed · 85 cited
  19. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 84 cited
  20. Phase 3 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Completed · 58 cited
  21. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 57 cited
  22. Phase 3 Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL Completed · 50 cited
  23. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  24. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 46 cited
  25. Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 36 cited
  26. Phase 4 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed · 35 cited
  27. Phase 3 A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy Completed · 35 cited
  28. Phase 3 Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Completed · 32 cited
  29. Phase 3 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Completed · 28 cited
  30. Phase 3 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Completed · 24 cited
  31. Phase 4 Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) Completed · 22 cited
  32. Phase 4 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Completed · 17 cited
  33. Phase 4 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection Completed · 16 cited
  34. Phase 3 A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy Completed · 15 cited
  35. Phase 3 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Completed · 14 cited
  36. Phase 3 An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation Completed · 12 cited
  37. Phase 3 Double Cord Versus Haploidentical (BMT CTN 1101) Completed · 10 cited
  38. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 10 cited
  39. Phase 3 A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed · 10 cited
  40. Phase 3 A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. Completed · 1 cited
  41. Phase 3 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Completed
  42. Phase 4 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed
  43. Phase 4 Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures Completed
  44. Phase 4 Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Completed

Showing the 50 most-cited and recently-updated of 814 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
Oncology Meta-analysis
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Jun 12, 2026
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Hematology RCT
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Jun 8, 2026
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
Drug Pipeline Meta-analysis
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
medRxiv Jun 4, 2026
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Oncology Sys. Review
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
Frontiers Jun 4, 2026
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Hematology Meta-analysis
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Jun 1, 2026
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Diabetes & Endocrinology Sys. Review
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Frontiers Jun 1, 2026
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Allergy & Immunology Sys. Review
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Frontiers Jun 1, 2026
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
Hematology FDA Approval
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
FDA May 30, 2026
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
Hematology Meta-analysis
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Frontiers May 29, 2026
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations
Drug Pipeline Sys. Review
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations Scientists examine how sugar metabolism affects acute myeloid leukemia cells
This narrative review examines glycolytic enzymes and glycolytic metabolism within acute myeloid leukemia (AML) cells. The authors synthesiz…
This review looks at how glycolytic enzymes and metabolism impact acute myeloid leukemia cells, offering new insights into this serious bloo…
Frontiers May 25, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Hematology Sys. Review
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
Frontiers May 15, 2026

Research across Cancer

Related studies from across the Cancer family.

Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
Allergy & Immunology Sys. Review
Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Frontiers Jun 11, 2026
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing
Drug Pipeline Sys. Review
Review discusses pharmacogenomic biomarkers for pediatric B-ALL chemotherapy dosing New review looks at using genetic tests to adjust cancer drug doses for kids
This narrative review examines the role of pharmacogenomic biomarkers and genotype-guided dose adjustments in pediatric B-cell acute lymphob…
A recent review suggests that checking specific genes before treatment can help doctors give the right amount of chemotherapy to children wi…
Frontiers May 24, 2026
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response
Pediatrics Sys. Review
Review of a case of Down syndrome T-ALL with complex karyotype and treatment response Boy with Down syndrome beats rare leukemia after tailored chemo
This narrative review and case report describes a 7-year-old boy with Down syndrome and T-cell acute lymphoblastic leukemia treated with AIE…
A 7-year-old with Down syndrome and a rare T-cell leukemia achieved remission after tailored chemotherapy, despite severe complications.
Frontiers May 18, 2026
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Oncology RCT
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
May 3, 2026
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
Allergy & Immunology Cohort
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Frontiers Apr 27, 2026
Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient
Oncology Sys. Review
Review compares 68Ga-pentixafor and 18F-FDG PET/CT in a single CLL patient A New Scan Spots a Tricky Blood Cancer Far More Clearly
This case report and review of literature evaluates diagnostic performance of 68Ga-pentixafor versus 18F-FDG PET/CT in a 60-year-old woman w…
A new PET scan tracer spots chronic lymphocytic leukemia more clearly than standard imaging, helping doctors see disease extent in patients …
Frontiers Apr 18, 2026
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Oncology Sys. Review
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Frontiers Apr 16, 2026
Meta-analysis of HSCT with treosulfan in Ataxia Telangiectasia patients shows mixed survival outcomes and significant toxicities
Hematology Meta-analysis
Meta-analysis of HSCT with treosulfan in Ataxia Telangiectasia patients shows mixed survival outcomes and significant toxicities A Teen With a Rare Disease Beat Leukemia After a Risky Transplant
This systematic review and meta-analysis evaluated hematopoietic stem cell transplantation (HSCT) using treosulfan in 16 patients with Ataxi…
A 16-year-old with a rare genetic disease survived leukemia after a tailored stem cell transplant, offering new hope for others with this fr…
Frontiers Apr 16, 2026
Meta-analysis finds global BLV prevalence of 23.24% in cattle, with decline after 2018
Oncology Meta-analysis
Meta-analysis finds global BLV prevalence of 23.24% in cattle, with decline after 2018 Cattle Virus Hides in China While Global Numbers Drop
This meta-analysis of 44 studies synthesizes global and Chinese data on bovine leukemia virus (BLV) prevalence in cattle.
A hidden outbreak of a cancer-causing virus in Chinese cattle farms is growing fast even as the rest of the world sees fewer cases.
Apr 16, 2026
Review supports Allo-HSCT for BCR-ABL(+) AML with TKI and chemotherapy
Oncology Sys. Review
Review supports Allo-HSCT for BCR-ABL(+) AML with TKI and chemotherapy A New Hope for Rare Blood Cancer Patients
This case report and literature review addresses the treatment of BCR-ABL(+) acute myeloid leukemia.
Doctors helped a patient with rare BCR-ABL positive leukemia survive by combining drugs, chemotherapy, and a stem cell transplant.
Frontiers Apr 16, 2026
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Oncology Cohort
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
medRxiv Apr 16, 2026
Review of pediatric B-ALL CAR-T therapy identifies RAS mutation outcome predictor
Oncology
Review of pediatric B-ALL CAR-T therapy identifies RAS mutation outcome predictor New Test Predicts CAR-T Success in Kids
This narrative review synthesizes observational data from 86 pediatric patients with relapsed or refractory B-cell acute lymphoblastic leuke…
A new test can spot hidden genetic risks before a child starts powerful CAR-T cancer therapy.
medRxiv Apr 16, 2026

Questions about leukemia

Can perinatal factors increase the risk of childhood acute leukemia?

Research shows that high birth weight, maternal diabetes, hypertension, history of abortion, and cesarean sections are linked to a higher risk of childhood acute leukemia.

Full answer →
How does a prehabilitation program help leukemia patients before chemotherapy starts?

A prehabilitation program combining exercise, nutrition, and psychological care helps leukemia patients before chemotherapy by improving walking distance, reducing fatigue, and lowering anxiety and depression.

Full answer →

All leukemia Articles